Dr Christopher Boyd


I'm a scientist working in the Medical Genetics Section of the Centre for Genomic and Experimental Medicine. My background is in prokaryotic molecular biology, with a particular interest in plasmids. Over the years this has evolved into a career in human gene therapy, a research field that impinges on all aspects of biology. I lead the section's cystic fibrosis gene therapy group, which forms part of the UK CF Gene Therapy Consortium (www.cfgenetherapy.org.uk), a collaboration between Imperial College, and the universities of Edinburgh and Oxford. The Consortium has completed a major Phase 2b clinical trial of non-viral gene therapy for CF: Scottish patients attended the Western General Hospital arm of the study. I am a member of the Consortium's strategy group.

My primary research interest is in the pre-clinical development of gene therapy, with a focus on vectorology, though more broadly I am interested in many aspects of genomic engineering.

My principal affiliation is to CGEM within the IGMM, but I also have research links to the Roslin Institute, working closely with Gerry McLachlan and David Collie, and am affiliated to the Centre for Inflammation Research. In addition, I am developing a research collaboration on gene therapy for Primary Ciliary Dyskinesia with Pleasantine Mill and her group in the MRC HGU